As of September 13, 100 participants have participated in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 MDMA-assisted therapy studies for the treatment of PTSD.
You are eligible to participate in this study if you completed participation in our MP16, MP17, MAPP1, MAPP2 or MAPPUSX studies at least 6 months ago. This long-term follow up study is conducted remotely. If you have not yet participated and would like to, please reach out to the study team at mapsfollowup@ucsf.edu.
